On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food...